Svetlana Pak

Director, KNCV Representative Office in Central Asia

Svetlana Pak is a medical doctor with over 30 years of professional experience in public health, and TB control programme and operational research in Central Asia (Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, and Uzbekistan).

Svetlana has co-authored several publications and is an expert in TB control policies and strategies, the programmatic management of, and the introduction of new drugs and treatment regimens for, of drug-resistant TB, patient centered care, ambulatory TB-care, TB related stigma, TB control in key and vulnerable populations, private sector engagement, and operational research. Previously Svetlana was the Project Coordinator for the TB Control in Prisons project in Kazakhstan and has experience in project design and management, TB program’ assessment and monitoring, training healthcare providers, and building partnerships with donors, key stakeholders, local non-governmental organizations and implementing partners.

Within KNCV, Svetlana provides technical assistance to national TB programs and local organizations, working with them to support the development / revision of TB policies and strategic plans and the adoption and implementation of new approaches and tools for the diagnosis and treatment of drug resistant TB. Svetlana also supports the introduction of stigma reduction interventions and monitoring and evaluation of TB programs, and drafting The Global Fund proposals. As KNCV representative Svetlana is responsible for the implementation of KNCV projects and activities in Kazakhstan.

Recent Publications:

  1. Klinkenberg E, van den Hof S, Tursynbayeva A, Kipruto H, Wahogo J, Pak S, Kutwa A, L’Herminez R. Integration of HIV in tuberculosis drug resistance surveillence in Kazakhstan and Kenya, Int J Tuberc Lung Dis. 2012 May;16(5):615-7. doi: 10.5588/ijtld.11.0262. Epub 2012 Mar 8.PMID: 22409816
  2. Kaliakbarova, S. Pak, N. Zhaksylykova, G. Raimova, B. Temerbekova and S. van den Hof. Psychosocial Support Improves Treatment Adherence Among MDR-TB Patients: Experience from East Kazakhstan, The Open Infectious Diseases Journal, 2013,7, (Suppl I; M7), 60 – 64
  3. van den Hof S, Tursynbayeva A, Abildaev T, Adenov M, Pak S, Bekembayeva G, Ismailov S. Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan. Int J Tuberc Lung Dis. 2013 Apr;17(4):526-31. doi: 10.5588/ijtld.12.0703.PMID: 23485387
  4. van Kampen SC, Tursynbayeva A, Koptleuova A, Murzakhmetova Z, Bigalieva L, Aubakirova M, Pak S, van den Hof S. Effect of Introducing Xpert MTB/RIF to Test and Treat Individuals at Risk of Multidrug-Resistant Tuberculosis in Kazakhstan: A Prospective Cohort Study. PLoS One. 2015 Jul 16;10(7):e0132514. doi: 10.1371/journal.pone.0132514. eCollection 2015.PMID: 26181578


read all the KNCV publications

KNCV has been fighting TB since its establishment in 1903. Over the past 120 years, the organization has acquired indispensable knowledge and experience in the field of effective TB prevention and care, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework and integrity
Our patroness
Partner with us


De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.